Auna (AUNA) Q2 2026 Earnings Call Transcript

Auna (AUNA) reported Q2 2026 results with 9% revenue growth driven by volume and higher complexity services. Adjusted EBITDA declined 9% due to margin pressures in Mexico and Colombia, and billing penalties in Peru. Mexico saw 7% surgery and 20% oncology volume growth, while Peru achieved 8% revenue growth. Colombia's adjusted EBITDA increased 18% sequentially. Leverage decreased to 3.6x, and cash increased 43% year-over-year.

Original reporting
Published Aug 25, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Auna (AUNA) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$AUNANeutralMed
01

Why it matters

The earnings release provides fresh data on revenue growth, cash generation, and operational challenges, informing short‑term trading decisions.

02

Market read

Auna's earnings update is the primary catalyst for its stock movement and may influence other Latin American health‑care peers.

03

What to watch

Potential impact of new tax and labor cost changes in Mexico on future profitability.

Relevance 7/10Novelty 7/10Timing: post-earnings release

Background

Auna operates a regional health‑care platform across Peru, Mexico, and Colombia, recently expanding high‑complexity services.

Company-level read

Ticker impact

$AUNANeutralMedium confidence
Context

Q2 2026 earnings call disclosed 9% revenue growth, margin pressure and adjusted EBITDA decline, providing fresh financial guidance.

Expected impact

Potential modest upside if guidance beats expectations; downside risk if margins remain pressured.

Evidence & confidence

Strong top-line growth offsets EBITDA decline; investors will focus on cash flow and guidance for H2.

Market effects

Highlights growth in Latin American healthcare services and potential for further consolidation.

Positive for Peru, Mexico, and Colombia healthcare markets.

Limited to investors focused on emerging market health stocks.

Counterpoint

Margin pressure and EBITDA decline may signal underlying cost issues despite revenue growth.

Key entities

  • Suso Zamora

    Executive Chairman and President of Auna

  • Gisele Remy

    Chief Financial Officer of Auna

Related articles

$AUNAMed

Auna S.A. (AUNA) Stock Falls on Q3 2026 Earnings

Auna S.A. (AUNA) reported Q3 2026 revenue of $384.7M, up 19.4% YoY, with net income falling 57.4% to $5.9M. Operating cash flow rose 38.9% to $77.6M. Insiders made 6 purchases and 1 sale in the past 6 months. Hedge funds showed mixed activity, with some increasing and others decreasing positions.

$AUNAMed

AUNA S.A. (AUNA): Financial results for Q3 2026

AUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 3Q26 Financial Results Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026; Mexico Returns to Year-over-Year Adjusted EBITDA Growth; Profitability Pressured by Specific Headwinds in Colombia and Peru Leverage Impro

$AUNAHigh

Why is Auna stock dropping today?

Auna SAA ADR stock fell 9.2% to $4.91 after revising its 2026 profitability outlook, citing higher cancer diagnosis costs in Colombia. The company maintained its revenue growth target but saw a sell-off amid broader market declines. The stock dropped to a session low of $4.55, nearing its 52-week low of $4.09.

$AUNAMed

Auna Q2 Earnings Call Highlights

Auna reported Q2 revenue growth in Mexico (4% YoY), Peru (8%), and Colombia (13%), but adjusted EBITDA varied. Mexico's EBITDA declined 16% YoY due to investments, while Peru's was flat due to billing penalties. Colombia's EBITDA fell 12% YoY but rose 18% sequentially. The company reaffirmed its full-year guidance, expecting 12% FX-neutral revenue growth and adjusted EBITDA growth toward the low end of its 10-14% target range, excluding Peru's billing penalties. Cash flow and leverage improved,